The UK and US have reached a major trade agreement that will maintain no levies on UK medicine exports going into the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has committed to increase funding on medicines through the National Health Service (NHS). This move secures that import taxes on these key exports will be held at zero for a timeframe of 36 months.
This development is in response to previous statements to hike import taxes on branded pharmaceutical products, with figures discussed as high as 100%.
"This agreement with the Britain bolsters the worldwide climate for innovative medicines and brings much-needed balance to transatlantic medicine commerce," an announcement declared.
Commercial Impact
Drugs are one of the UK's largest goods shipped to the United States, which is easily the biggest market for leading companies like GSK and AstraZeneca.
Trade data show that in the one-year period leading up to last September, the UK shipped pharmaceutical products totaling billions to the US. This figure made up a significant portion of total UK exports in that timeframe.
"This guarantee safeguards employment, increases capital expenditure and facilitates the UK to become a worldwide center for life sciences," the Business and Trade Secretary stated.
Detailed UK Commitments
The agreement involves several specific pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a aim to increase total NHS spending on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The amount drug companies must pay back to the NHS to prevent overspending will be limited at fifteen percent. Last year, rebates topped twenty percent.
Broader Context
The pact comes amid a protracted dispute between the drug companies and the British authorities over spending levels and approval rates.
The disagreement were intensified by arguments that American customers were charged several times more for the equivalent treatments than people in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been halted or abandoned, while major expansions have been directed toward US facilities.
The Science Minister acknowledged that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had declined as a proportion of its resources over the previous ten-year period.
